first pan-KRAS inhibitor advances to clinical testing

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing  Results were presented from the company ’s pan-KRAS program including BI 1701963, which is being investigated alone and in combination with MEK inhibition in an ongoing Phase I clinical study in cancer patientsAround 15% off all cancers can potentially be blocked by this compound, targeting all major oncogenic KRAS mutations   Dual KRAS pathway blockade combining pan-KRAS and MEK inhibition has potential to further enhance efficacy
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news